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Abstract
Background: The establishment of therapeutic regimens for mycobacteriosis depends on the accurate identification
of Mycobacterium species, and misdiagnosis can result in inappropriate treatment and increased mortality of patients.
Differential diagnosis among Mycobacterium species has been made by conventional phenotypic and biochemical
tests after a long culture period. Specialized molecular diagnostics of mycobacteria allows rapid detection and species
identification; however, such tests are not available in public health programs. Our aim was to demonstrate the clinical
implications of erroneous diagnosis by performing molecular genotyping of mycobacterial infections in patients that
were diagnosed based on symptoms, culture and bacilloscopy.
Methods: Culture samples of mycobacterial infections from 55 patients clinically diagnosed as tuberculosis in 2013
and 2014, based on conventional methods, were identified by PCR -RFLP and results are discussed.
Results: We have confirmed 35 (63.6 %) positive samples as M. tuberculosis, but 18 (32.7 %) were identified as
non-tuberculous mycobacteria (M. avium type 1, M. avium type 2, M. kansasii type 1 type 1, M. mucogenicum, M.
chelonae, M. terrae type 3, and 1 unknown RFLP pattern) and two were negative. Regarding clinical diagnosis,
61.8 % (34/55) was classified as pulmonary tuberculosis. It is important to emphasize that 36.4 % (20/55) of samples
were misdiagnosed by conventional methods, and 11 (61.1 %) of the HIV positive patients (18/55) were NTM-
coinfected.
Conclusion: The identification of species in mycobacterial infections is essential for correct diagnosis and choice of
treatment regimen, and misdiagnosis by conventional tools can lead to chronic disease, increased resistance and
death.
Keywords: Mycobacteria, PCR-RFLP, Molecular Diagnosis
Background
Despite the large number of Mycobacterium species [1],
M. tuberculosis (MTB) is still one of the major causes of
human diseases and mortality worldwide. The proportion
of mycobacterial infections due to nontuberculous myco-
bacteria (NTM) seems to be increasing in relation to TB
infections, probably due to improved diagnosis through
molecular analysis, but also due to increasing incidence of
immunocompromised patients with HIV infection [2, 3],
chronic inflammatory diseases [4], organ-transplantation
[5], and dermatological diseases [6], leading to significant
NTM-related deaths in individuals older than 55 years of
age [7]. In Brazil, NTM infections have become an
epidemiological emergency, especially after the outbreak
of rapidly growing mycobacteria in post-surgical infections
from 2003 to 2009 [8]. All these variable co-morbidities
together with factors that remain unknown pose great
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challenges to the epidemiological analysis of NTM diseases
and application of proper treatments, greatly due to their
misdiagnosis.
Differentiation between mycobacteria species is typically
made in positive cultures based on phenotypic and bio-
chemical traits. Currently, the diagnostic methods used
are bacilloscopy and microbiological culture [9], but the
main method for bacilli detection is the Ziehl-Neelsen
specific staining technique; however, despite its simplicity
and low cost, it has a very low sensitivity (30 to 50 % of
the M. tuberculosis cases are negative). The microbio-
logical culture is generally used in suspected pulmonary
cases and in negative bacilloscopy, and allows detection
and isolation of mycobacteria for subsequent identification
of the isolated complex [9]. Despite its importance, the M.
tuberculosis culture is time consuming due to its slow
growth, and not always presents 100 % positivity [10].
Automated detection systems of mycobacteria, such as
the BACTEC 460 TB®, BACTEC 9000®, and the MGIT®
are promising, but they can also produce false-positive
results due to contamination by other bacteria [9].
In places without appropriate identification techniques,
the NTM diseases can be confounded with tuberculosis
due to the similarity of clinical symptoms, affected sites and
morphological characteristics of bacilli, leading to misdiag-
nosis and improper treatment, resulting in prolonged treat-
ment, chronic infections, drug resistance and increased
mortality [11].
The establishment of therapeutic regimens depends on
species identification of mycobacteria, which can be critical
for the adoption of appropriate therapy [12]. The mycobac-
teriosis treatment becomes even more complex due to in-
creasing resistance and low sensitivity to tuberculostatic
drugs. Therefore, for an efficient and proper treatment, the
identification of the causative agent and its drug sensitivity
are necessary in order to choose appropriate drugs [13].
Tools commonly used for diagnosis of tuberculosis in
resource-limited settings, such as the direct Ziehl-Neelsen
(DZN) staining and the direct fluorescent microscopy
(DFM) have been compared, which have missed 64 and
20 % of cases, respectively, supporting the concern that
using DZN alone may risk missing the majority of TB
cases [14]. The need for fast and reliable laboratory tests
for mycobacterial diagnosis resulted in the development
of molecular methods for detection and identification of
species directly from clinical specimens and/or from iso-
lated culture colonies. However, while some techniques
are simple, others have complex requirements, and the
incorporation of these tests within a country's national
health program must be carefully determined [15]. It is
important to consider that increasing antibiotic resistance
of pathogens associated with nosocomial infections and
laboratorial contamination also pose major challenges to
health programs, especially in regions with poor settings,
for which no single measures can solve this complex
problem. Developed nations must strategically aid those
regions to prevent the increased burden of antibiotic-
resistant mycobacteria due to the lack of proper diagnosis
and patients’ management.
Several molecular methods have been developed for
the identification of mycobacteria species [16]. Among
them, the PCR-RFLP (Restriction Fragment Length Poly-
morphism)-based method, despite its moderate complexity,
was shown to be fast, with good accuracy, and cost-
effective [17]. The method, also referred as PRA-hsp65,
amplifies and digests a portion of the hsp65 (65 kDa heat
shock protein) with restriction endonucleases, and is able
to detect the most important and common mycobacteria
species. This method has the advantages of having high
specificity, rapid results, and requires only two equipments;
a thermocycler and agarose gel electrophoresis [18].
Another technique that has been used to differentiate
mycobacteria species, and is gradually replacing the
conventional PCR, is the real-time PCR, which has the
advantages of releasing results in reduced time with
minimal manipulation, and higher sensitivity. However,
the this technique has some impediments, such as high
cost, besides not being able to identify many species in a
single reaction, frequently producing false-positive results
hindering the lack of standardization of this technique
[16]. Thus, even with the most advanced techniques,
PCR-RFLP continues to be the most useful tool for the
identification of mycobacteria species.
This study aimed to identify species of mycobacteria
present in samples of positive cultures from patients diag-
nosed with tuberculosis treated at the Clinical Hospital of
the Federal University of Uberlândia in the biennium 2013-
2014, and discuss the implications of misdiagnosis by using
only conventional bacilloscopy and culture methods.
Methods
Study design and patients
A transversal retrospective descriptive study was performed
in culture samples from all patients diagnosed with tuber-
culosis and treated at the Clinics’ Hospital of the Federal
University of Uberlândia during the biennium 2013-2014.
Age, sex, HIV status, and patient treatment time were
obtained in their medical records. Two or more cultures
were performed for each patient for clinical evaluation, and
only those positive cultures were subsequently used for
DNA extraction and analyses.
Sampling
Among 1380 cultures of suspected patients with myco-
bacterial infections, fifty-five clinical samples (bronchial
aspirate, cervical lymph nodes, bone marrow aspirate,
sputum, pleural liquid, vesicular fluid, bronchial lavage,
tracheal secretion, gastric aspirate, liquor, gingival injury,
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surgical scar and liver fragment) with positive and viable
cultures of Mycobacterium sp. were collected, which were
clinically diagnosed as tuberculosis. Important to emphasize
that the sample size does not represent the entire suspected
population. Negative culture samples were not investigated
by PCR, which is a limitation of this study.
Fifteen reference samples of mycobacterial species
were used for molecular standard patterns, which were
previously identified and donated by the Oswaldo Cruz
Foundation (FIOCRUZ/RJ): M. avium, M. abscessus, M.
fortuitum, M. terrae, M. peregrinum, M. smegmatis, M.
marinum, M. phlei, M. gordonae, M. kansasii, M. bovis,
M. szulgai, M. massiliense. The M. tuberculosis reference
strain was provided by the Instituto Hélio Fraga (Rio de
Janeiro, Brazil), and the M. leprae reference strain was
provided by the National Reference Center of Sanitary
Dermatology and Leprosy (CREDESH/HC/UFU, Uberlan-
dia, MG, Brazil).
Ethical statement
Culture samples from various tissues and body fluids of
patients with clinical diagnosis of tuberculosis from the
Infectious Diseases Ambulatory Service of the Clinics’
Hospital of UFU were obtained for molecular genotyping.
Informed Consents were obtained from all patients, who
were invited to participate in the study approved by the
Research Ethics Committee of the Federal University of
Uberlândia, under the process numbers CEP/UFU N. 123/
10 (Approval CEP 457/10, Tuberculosis) and CEP/UFU N.
355/11 (Approval CEP 097/12, HIV and co-infections).
Informed consents from two patients under 16 years of
age were also obtained from their parents.
Bacilloscopy and culture
Bacilloscopy and mycobacteria culture were performed
by the Laboratory of Clinical Pathology of the Federal
University of Uberlândia, according to the recommenda-
tions outlined in the National Manual of Tuberculosis
Surveillance and Other Mycobacteria [19]. Clinical symp-
toms that strongly indicate the presence of mycobacteria
and/or positive bacilloscopy for acid-fast bacillus resistant
(AFB) are criteria for confirmatory culture of patients’
samples. Duplicate cultures of different clinical specimens
were performed on Middlebrook 7H9 broth medium for
growth, storage, and subsequent DNA extraction. Results
regarding culture time and bacilloscopy were recorded.
DNA extraction
Positive cultures in the Middlebrook medium were heat-
inactivated at 95 °C for 15 min and processed in three
replicates. Subsequently, DNA extraction was performed
by the salting-out method [20].
DNA amplification and restriction endonuclease digestion
(PCR-RFLP)
The 439-bp fragment of the Hsp65 gene was amplified
using the Tb11 (5'-ACCAACGATGGTGTGTCCAT-3’)
and Tb12 (5′-CTTGTCGAACCGCATACCCT-3′) primers
modified from the protocol described elsewhere [18]. The
PCR reaction components for a final volume of 50 μL con-
sisted of: 25 μL of 2X PCR Master Mix [0.05 U/μL Taq
DNA polymerase, reaction buffer, 4 mM MgCl2, 0.4 mM of
each dNTP (dATP, dCTP, dGTP and dTTP) (Thermo
Scientific), 1.5 μL of 10 μM of each primer, 4 μL of sample
DNA (25 ng/μL) and 18 μL of ultrapure water. The PCR
reaction consisted of 45 cycles with the following condi-
tions: 1 min at 94 °C, 1 min at 60 °C, 1 min at 72 °C,
followed by a final extension of 10 min at 72 °C.
For endonucleases’ restrictions with BstEII and HaeIII,
15 μL of the PCR product was added to a mix containing
0.5 μL (5U) of the enzyme, 2.5 μL of restriction buffer (5X
buffer B), 0.2 μL of BSA and 11.3 μL of ultrapure water.
The BstEII reaction was incubated for 60 min at 60 °C and
the HaeIII reaction was performed at 37 °C for 3 h.
After restriction, 8 μL of digested products were added to
3 μL of running buffer of agarose gel (0.25 % bromophenol
blue, 40 % sucrose in water) and separated by 3 % agarose
gel electrophoresis in 0.5X TBE buffer. Fragments were
visualized under UV light using ethidium bromide as a
fluorescent DNA intercalator. A 25-bp molecular marker
was used for fragment sizing. Electrophoresis banding
patterns were submitted to algorithms described in the on-
line tool PRASITE (http://app.chuv.ch/prasite/index.html)
for species identification.
Diagnosis
Clinical diagnosis of mycobacterial infections performed
at the Clinics’ Hospital of Uberlândia is based on clinical
symptoms, bacilloscopy and bacterial growth time, and
the final interpretation is made by physicians, following
the standard protocol of the Brazilian Ministry of Health
[19]. Clinical diagnosis of tuberculosis is reached when
patients present clinical symptoms, positive bacilloscopy
and/or positive slow-growing culture for Mycobacterium
sp. All positive cultures that were clinically diagnosed as TB
were submitted to molecular identification of mycobacteria
species. Misdiagnosis was considered when the PCR-RFLP
identified other mycobacteria species that were different
from M. tuberculosis.
Treatment
Since patients with Mycobacterium sp. were initially diag-
nosed with tuberculosis, the first line of treatment chosen
was the standard regimen recommended by the Brazilian
Ministry of Health (2RHZE/4RH): two months of COC-
XIP 4 (rifampicin, isoniazid, pyrazinamide and etham-
butol), and four more months of rifampicin and isoniazid.
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Substitute treatments with other complementary drugs
were initiated when treatment failed, probably due to mis-
diagnosis or bacterial resistance. Medications commonly
used in suspected cases or with confirmed infection of atyp-
ical mycobacteria are: clarithromycin, ciprofloxacin, amika-
cin, cefoxitin, imipenem, doxycyclin or azithromycin.
Results
Patients’ data
In the period of 2013 to 2014, 55 positive mycobacterial
cultures were obtained from patients diagnosed with
tuberculosis attended at the Clinics’ Hospital of the Federal
University of Uberlândia. Considering the demographical
characteristics, 40 patients were male (72.7 %), with an
average age of 46 years old, ranging from 11 to 92 years
(Table 1).
Microbiological data
The observed frequency of mycobacterial species were:
63.6 % (35/55) of M. tuberculosis, 16.3 % (9/55) of M.
avium type 1, 3.7 % (2/55) of M. avium type 2, 3.7 % (2/
55) of M. kansasii type 1, 1.8 % (1/55) of M. intracellulare
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M. avium type 2 Standard
treatment
Under treatment











M. avium type 1 Standard
treatment
Died
33 36 + Gastric Aspirate - Myc. sp/
20 days
Miliary Tuberculosis M. avium type 2 Substitute
treatment
Died














M. kansasii type1 Standard
treatment
Under treatment




M. avium type 1 Standard
treatment
Completed treatment
38 42 + Liquor - Myc. sp/
16 days
Bone Tuberculosis M. avium type 1 Standard
treatment
Completed treatment






M. avium type 1 Standard
treatment
Completed treatment












Miliary Tuberculosis M. avium type 1 Standard
treatment
Completed treatment
52 59 + Gastric Aspirate - Myc. sp/
25 days
Miliary Tuberculosis M. avium type 1 Standard
treatment
Under treatment
54 77 - Surgical Scar - Myc. sp/
05 days
Bone Tuberculosis M. chelonae Substitute
treatment
Under treatment
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type 1, 1.8 % (1/55) of M. mucogenicum, 1.8 % (1/55) of
M. chelonae, 1.8 % (1/55) of M. terrae type 3, and 1.8 %
(1/55) presented an unknown pattern (HaeIII-150/110;
BstEII-235/210). Two patients diagnosed with TB clinical
symptoms (3.7 %) were both AFB and PCR-RFLP nega-
tives (Tables 1 and 2, and Fig. 1), probably due to misdiag-
nosis, although one of them presented a positive culture
with an unknown microorganism. Co-infections by more
than one mycobacteria species in the same sample were
not identified, since mixed RFLP patterns from primary
cultures were not observed. It is important to emphasize
that DNA extraction was performed in primary liquid
cultures (pools) and not from a single colony.
Among 35M. tuberculosis samples identified by PCR-
RFLP, 21 were AFB positive. For the positive NTM samples
(18/55; 32.7 %), 5 were AFB positives (3M. avium type 1
and 2M. kansasii) and 13 were AFB negatives (6M. avium
type 1, 2M. avium type 2, 1M. terrae type 3, 1M. Intrace-
lulare, 1M. mucogenicum, 1M. chelonae, 1 NTM with
unknown pattern). The two remaining samples were both
PCR and AFB negatives (Tables 1 and 2).
Culture vrs PCR-RFLP
Among the 35M. tuberculosis cultures identified by
PCR-RFLP, 30 presented slow growth (>15 days) and 5
had fast growth (<15 days). From the 9M. avium type 1
cultures, all had growth periods greater than 15 days. From
the two M. kansasii type 1cultures, one had 15-day growth
and one had no information about culture time. From the
two M. avium type 2 cultures, one presented growth in
more than 15 days and the other had no information. The
M. chelonae and M. mucogenicum cultures had growth
times lower than 10 days. The M. terrae type 3 culture grew
in 15 days. The NTM species with unknown patterns had
growth periods of more than 15 days. From the two nega-
tive cultures that were molecularly detected and typed, one
had no information about its culture time and the other
grew in 15 days (Tables 1 and 2).
Affected sites
Among TB clinically diagnosed samples, 61.9 % (34/55)
were found in the pulmonary site, in which 23 were M.
tuberculosis, four M. avium 1, two M. kansasii, one M.
intracellulare, one M. mucogenicum, one unknown NTM
and two were negative. Five samples involved unspecified
sites (9 %; 5/55), which were classified as M. tuberculosis
(3), M. avium 1 (1) and M. terrae (1). Disseminated infec-
tion (miliary tuberculosis) was reported in 11 % (6/55) of
the positive samples, including 3 M. tuberculosis, 2M.
avium 1 and 1M. avium 2. The 5.5 % (3/55) of positive
pleural sites were infected by M. tuberculosis.
Among the extra-pulmonary tuberculosis, 3.6 % (2/55)
were ganglionar (1M. tuberculosis and 1M. avium1), 3.6 %
(2/55) were bone-derived (1M. chelonae and M.avium1);
1.8 % (1/55) was vesical (M. tuberculosis); and 3.6 % (2/55)
presented affected meninges and liquor (M. tuberculosis
and M. avium 2) (Table 2).
HIV Co-infection
Regarding HIV co-infections, we have found that 32.7 %
(18/55) of the patients were HIV positive and among
them, 44.4 % (8/18) were M. avium type 1, 33.3 % (6/18)
were M. tuberculosis, 11.1 % (2/18) M. avium type 2, and
11.1 % (2/18) were PCR negative (Table 2). Therefore,
56 % of co-infections with HIV were caused by NTM.
Misdiagnosis and inappropriate treatment
All patients were clinically diagnosed with tuberculosis,
but only 63.6 % (35/55) were confirmed as M. tuberculosis
by PCR-RFLP; therefore, 36.4 % (20/55) of the patients
were misdiagnosed. Among them, 18 samples were identi-
fied as NTM infections, and 2 were negatives (Tables 1
and 2).
Concerning the treatment, 89 % (49/55) of patients
were submitted to the standard treatment for tuberculosis
[2RHZE/4R - two months of COCXIP 4 (rifampicin, iso-
niazid, pyrazinamide and ethambutol) followed by four
additional months with rifampicin and isoniazid], and only
11 % (6/55) had a substitute treatment for atypical myco-
bacteria, which included auxiliary drugs to the standard
treatment, due to the chronic infection. Among those 6
chronic patients, 5 (7.3 %) were NTM-infected and had
their treatment replaced by the appropriate treatment, and
one patient was negative (Tables 1 and 2). Therefore, 13
out of 18 NTM-identified were inappropriately treated as
tuberculosis.
Discussion
Nontuberculous mycobacteria infections have increased
considerably in Brazil and worldwide, probably due to
the reduced incidence of tuberculosis as a consequence of
treatment improvements, which in turn make individuals,
especially immunosuppressed ones, more vulnerable to
opportunistic mycobacteria. Although this fact was first
evidenced in developed countries, it has been increasingly
observed in developing countries [21]. This augment can
also be justified by the deployment of new techniques for
species identification, which have improved the detection
of NTM species, contributing to a better understanding of
the epidemiology of mycobacterial infections.
In Brazil, there are few studies about nontuberculous
mycobacteria epidemiology [9, 17, 22], because NTM infec-
tions have no obligatory notification, and besides none of
the public hospitals and health services perform molecular
methods for species identification. Also, these reports are
isolated studies, mainly in the Southeastern states, with dif-
ferent methodologies, unavailable in most of the Brazilian
states [22], so comparisons among them are difficult. The
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Table 2 Patients’ characterization according to the molecular identification of mycobacteria species
Patients’ Characterization Molecular Diagnosis (PCR-RFLP)




M. kansasii M. intracellulare
type 1
M. mucogenicum M. chelonae M. terrae
type 3
MNT unknown Negative Total
Gender Male 26 6 2 2 1 0 1 0 0 2 40
Female 9 3 0 0 0 1 0 1 1 0 15
Age <25 years 4 2 1 0 0 0 0 0 0 0 7
25-50 years 17 3 1 0 0 1 0 0 0 1 23
>50 years 14 4 0 2 1 0 1 1 1 1 25
AFB Positive 21 3 0 2 1 0 0 0 0 0 27
Negative 14 6 2 0 0 1 1 1 1 2 28
Culture time >15 days 30 9 1 1 1 0 0 1 1 0 44
<15 days 5 0 0 0 0 1 1 0 0 0 7





23 4 0 2 1 1 0 0 1 2 34
Unspecified
tuberculosis
3 1 0 0 0 0 0 1 0 0 5
Miliary tuberculosis 3 2 1 0 0 0 0 0 0 0 6
Pleural tuberculosis 3 0 0 0 0 0 0 0 0 0 3
Lymph Node
tuberculosis
1 1 0 0 0 0 0 0 0 0 2
Bone tuberculosis 0 1 0 0 0 0 1 0 0 0 2
Vesical tuberculosis 1 0 0 0 0 0 0 0 0 0 1
Meningitis -
tuberculosis
1 0 1 0 0 0 0 0 0 0 2
HIV Status HIV positive 6 8 2 0 0 0 0 0 0 2 18













majority of investigations present restricted species
identification of NTM, and only two reports associate
with epidemiological data, infected body parts, diagno-
sis and treatment [17, 23]. In Uberlândia, a city with
high flow of migrants and rapid development in central
Brazil, there are still no records of mycobacterial infections.
This study performed in a reference hospital of Uberlan-
dia, Minas Gerais State, Brazil, identified mycobacteria
species by PCR-RFLP, and compared results of patients’
samples that were clinically diagnosed as tuberculosis infec-
tion, according to a conventional method algorithm using
clinical symptoms, bacilloscopy and culture. We opted for
the PCR-RFLP method due to its rapidity, low cost, repro-
ducibility, and capability of identifying a large number of
NTM species [17, 24]. Another reason was to evaluate its
effectiveness for routine implementation in the Brazilian
unified health system (SUS). Here, we showed a significant
percentage of misdiagnosis (36.4 %), which has led to in-
appropriate treatment of 13 out of 18 patients (72.2 %),
demonstrating the importance of species identification.
When we characterized the patient profiles with myco-
bacteriosis, we found that about 70 % were male and the
mean age was 46 years, which is corroborated by a report
elsewhere [25] that found that the majority of affected
patients was male (76 %) with an average age of 40 years
old. This may be partially explained by the predominance
of middle-age men migrants that come from low-income
regions looking for better opportunities.
The identification of M. tuberculosis infections in 63.6 %
(35/55) of samples is consistent with other studies that
found a higher prevalence of MTB; 67 % [26], 57.5 % [27],
78.6 % [28] and 77 % [29]. Despite the higher occurrence
of MTB, it has been shown elsewhere that the MTB
frequency is declining over the years, while the NTM
frequency is significantly increased, with prevalence ran-
ging from 9.1 % in 2003 to 31.9 % in 2009 [28]. The
increased NTM prevalence over time is due to the im-
provement of techniques for identification and to better
tuberculosis diagnosis and treatment, and could also be
partially attributed to the increase in immunosuppressed
people, with HIV, organ transplantation, and other causes.
In most studies similar to this, the NTM complex
most commonly associated with the clinical disease were
M. avium, M. fortuitum, M.kansasii, M. chelonae, M.
gordonae and M. abscessus [17]. In this study, among the
potentially pathogenic NTM species, we observed 50 %
(9/18) M.avium type 1, 11.1 %M. avium type 2, 5.5 %
M. intracellulare, M. kansasii type 1 (11.1 %) and M.
chelonae (5.5 %). We also found two rarely pathogenic
species, such as 1M. mucogenicum (5.5 %) and 1M. ter-
rae type 3 (5.5 %), although they are not commonly
associated with diseases they are found in the environ-
ment and in potable water distribution systems due to
its resistance potential in disinfection procedures [21].
We also identified a NTM sample with unknown pat-
tern, for which DNA sequencing will be performed to
determine the existence of a new species.
Regarding the mycobacteria culture, it is important to
note that despite the slow growth of M. tuberculosis (2-8
weeks), 5 MTB cultures presented fast growth (<15 days)
Fig. 1 Frequency distribution of mycobacteria species identified by PCR-RFLP in patients clinically diagnosed with tuberculosis
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(Additional file 1: Table S1), probably due to the high
inoculum concentration, which may have also interfered
in the clinical diagnosis. These five cases were correctly
treated as MTB, because all cases are initially submitted
to TB treatment regimen; however, because of the lack
of molecular analysis, the treatment could only be con-
tinued as NTM infection if it had failed, and this may
have had an important clinical impact on NTM cases
that may lead to chronic disease, but fortunately this
was not the case.
The bacilloscopy is not a reliable method too, since it can
be negative in 30 to 50 % of cases of individuals infected
with M. tuberculosis [9]. In this study, we found that 38 %
of the MTB positive samples were AFB negative, whereas
72 % of the NTM infections were AFB negative.
It is common to find high rates of immunosuppressed
individuals affected by NTM species, especially the M.
avium complex [30]. We found 55 % (10/18) of HIV
positives co-infected with M avium type 1 and 2 species.
However, it is interesting to highlight that 45 % of NTM
infections occurred in supposed immunocompetent indi-
viduals. Epidemiologists admit that for this type of patient
it is important to recognize other risk factors associated
with higher chances of developing NTM, such as pre-
existing pulmonary lesions or chronic diseases that cause
major structural damage, predisposing the individual to the
development of NTM pulmonary disease [31, 32].
It is important to emphasize that NTM positivity in clin-
ical samples must be carefully interpreted, and may have
three meanings: (a) the mycobacterium is the etiological
agent, in which diagnosis is supported by clinical signs and
by repeated isolation of this bacillus in the same patient, or
by a single isolation in the case of samples taken asep-
tically; (b) the mycobacterium may have colonized the
sample, but has no clinical significance, which may have
occurred due to the use of contaminated equipment, a
common phenomenon called “pseudo-infection”; or (c)
the detection of mycobacteria in clinical samples comes
from laboratory contamination (contaminated solu-
tions), which can be easily verified with proper controls
or by observing if the same mycobacteria was isolated
from other samples analyzed in the same day [24].
The diagnosis performed at the Clinics’ Hospital of
Uberlândia, takes into account only bacilloscopy, cul-
ture time and symptoms for clinical diagnosis, and
among 55 patients diagnosed as tuberculosis, 35 were
correctly identified as MTB (63.6 %) when verified by
PCR-RFLP, but 36.4 % (20/55) of these samples were
either NTM-infected (18) or negative (2), configuring
misdiagnosis. The disease caused by NTM in most
cases is pulmonary or disseminated [33], but our
findings, demonstrated that the largest number of pul-
monary disease (51 %; 18/35) occurred primarily in tu-
berculosis patients, while for the NTM, 39 % (7/18)
were pulmonary, and 16.6 % (3/18) were miliary disease.
Misdiagnosis of this group of patients may have been the
cause of multiple sample collections, and patients’ phys-
ical, psychological, economic and social suffering due to
the inadequate treatment. As an additional consequence,
NTM strains may have become antibiotic resistant,
prolonging the treatment, and in most cases resulting in
chronic disease, leading to many hospitalizations and un-
successful treatments, and increasing the chances of liver
damage and mortality [9].
The recommended treatment for MTB applied to
NTM-infected patients, or for NTM applied to MTB
patients, or for NTM with non-specific schemes may
lead to major complications, since different therapeutic
regimens should be adopted for each group. The anti-
microbial and the treatment time varies according to
the species, and some NTM are resistant to the drugs
used for tuberculosis treatment, and not all NTM are
sensitive to the same treatments, which may result in
chronic infections [12]. Available studies consider the
treatment of the NTM disease quite complex, and rec-
ommend the observation of three factors to guide the
therapeutic decision: the bacillary load, the isolated
species and the presence of clinical progression of the
disease. The establishment of appropriate treatment
regimens may be complicated by the large number of
NTM species with differential antimicrobial susceptibil-
ity profiles. Currently, at international level, treatment
recommendations for NTM infections are based on a
series of case reports that consider the treatment expe-
riences of the M. avium and M. kansasii complex,
which constitute most of the cases described in the
literature [34, 35].
Conclusion
Briefly, we have demonstrated that conventional methods
used to detect mycobacterial infections, AFB and culture,
have led to significant uncertain diagnoses, and considering
that species identification is essential to choose the correct
therapeutic regimen, it is expected then that mycobacteria
resistance, chronic infections, and poorer outcomes may be
direct consequences of such misdiagnosis. We suggest that
urgent molecular identification of mycobacteria species and
resistance tests are incorporated into public health systems
in regions with resource-poor settings in order to reduce
morbidity by adopting appropriate therapeutic regimens,
and to prevent the increased burden of antibiotic-resistant
mycobacteria.
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